Annovis Bio, Inc. Common Stock (ANVS)
2.7700
+0.00 (0.00%)
NYSE · Last Trade: Aug 13th, 5:06 AM EDT
Detailed Quote
| Previous Close | 2.770 |
|---|---|
| Open | - |
| Bid | 2.640 |
| Ask | 2.770 |
| Day's Range | N/A - N/A |
| 52 Week Range | 1.110 - 10.54 |
| Volume | 0 |
| Market Cap | 53.98M |
| PE Ratio (TTM) | -1.601 |
| EPS (TTM) | -1.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 289,964 |
Chart
About Annovis Bio, Inc. Common Stock (ANVS)
Annovis Bio Inc is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly conditions like Alzheimer's disease and Parkinson's disease. The company is dedicated to advancing its proprietary platform designed to target and modulate underlying pathologies associated with these diseases. Annovis Bio aims to improve patient outcomes by researching and delivering potential treatments that can enhance cognitive function and overall quality of life for individuals affected by debilitating neurological disorders. Read More
News & Press Releases
Annovis Bio (NYSE:ANVS) reported a narrower Q2 2025 loss of $0.32/share vs. $0.41 estimate, with $17.1M cash on hand. Progress in Phase 3 Alzheimer's trial and IP updates highlight clinical focus. Stock dipped slightly post-earnings.
Via Chartmill · August 12, 2025
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · August 12, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical company advancing treatments for neurodegenerative diseases, announced the successful transfer and expansion of its intellectual property to fully cover both the original and new crystalline forms of buntanetap. The comprehensive patent portfolio, now protected through 2046, includes composition of matter, mechanism of action, and use in multiple indications. The new form offers improved stability with bioequivalence confirmed in animal and human studies, as presented at the 2025 Alzheimer’s Association International Conference.
Via Investor Brand Network · August 7, 2025
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap.
By Annovis Bio Inc. · Via GlobeNewswire · August 7, 2025
Via Benzinga · July 22, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.
Via Investor Brand Network · June 26, 2025
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap.
By Annovis Bio Inc. · Via GlobeNewswire · June 26, 2025
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · June 25, 2025
Via Benzinga · June 25, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 25, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
Annovis Bio (NYSE: ANVS), a clinical-stage platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has received formal acceptance from the New York Stock Exchange of its compliance plan addressing minimum market capitalization and stockholders’ equity requirements. The NYSE granted the company an 18-month window, beginning March 26, 2025, to regain compliance.
Via Investor Brand Network · June 20, 2025
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.
By Annovis Bio Inc. · Via GlobeNewswire · June 19, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The webcast will include a brief presentation followed by a live Q&A session open to shareholders, patients, and other stakeholders.
Via Investor Brand Network · June 5, 2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
By Annovis Bio Inc. · Via GlobeNewswire · June 5, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 4, 2025
Via Benzinga · May 15, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor conferences, including Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and AD/PD(TM) 2025 in Vienna. Cash and equivalents rose to $22.2 million as of March 31, 2025, while R&D expenses fell year-over-year to $5.0 million.
Via Investor Brand Network · May 14, 2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · May 13, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
Annovis Bio (NYSE: ANVS), announced the appointment of Hui Liu as Director of Biostatistics as the company advances its pivotal Phase 3 Alzheimer’s disease trial. Liu brings over 19 years of experience in clinical trial design, analysis and regulatory submission support across multiple therapeutic areas. Annovis stated that Liu’s expertise will help reinforce the scientific integrity of its data and enhance regulatory strategies as it develops transformative therapies for neurodegenerative disorders.
Via Investor Brand Network · April 29, 2025
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.
By Annovis Bio Inc. · Via GlobeNewswire · April 29, 2025
Via Benzinga · April 21, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · April 21, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day period was approximately $37.9 million, while its stockholders’ equity as of Dec. 31, 2024, was $9.3 million—both below the $50 million threshold. Annovis will submit a compliance plan within 45 days and may remain listed during an 18-month cure period if the NYSE accepts the plan. Its stock will continue trading under the “ANVS” symbol with a “.BC” indicator reflecting noncompliance status.
Via Investor Brand Network · March 28, 2025